GATA-1 Inhibitors
2 drugsAbout GATA-1
GATA-1 is a transcription factor that binds DNA to control gene expression, crucial for red blood cell and megakaryocyte development. It regulates blood cell production, making it a key target for therapeutic intervention.
GATA-1 is targeted therapeutically to modulate blood cell regulation, particularly in cardiovascular diseases. Currently, there is no genetic evidence data available linking GATA-1 mutations to specific diseases.
GATA-1 is targeted by 2 approved small molecule drugs, including AGRYLIN (anagrelide) from Takeda. These drugs are used in cardiovascular and other therapeutic areas.
Top GATA-1 Drugs
The competitive landscape includes Cipla and Takeda, each with approved drugs targeting GATA-1.
Limited number of players indicates low market saturation, creating opportunities for new entrants.
GATA-1 Drug Modality Landscape
Modalities
Routes of Administration
GATA-1 is amenable to small molecule drugs, with oral options available for convenient dosing.
Focus on small molecules presents an opportunity to explore alternative modalities like antibodies or gene therapies.
GATA-1 Clinical Trials 6 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on GATA-1. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 2 | 0 | 2 | 0 | 0% |
| Phase 3 | 4 | 2 | 0 | 2 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
GATA-1 Drug Approval Timeline (1997 - 2005)
Thrombocythemia secondary to myeloproliferative neoplasms
The first GATA-1 targeting drug was approved in 1997, with the most recent approval in 2005.
The approval timeline shows a stagnant market, suggesting potential for innovation with novel GATA-1 modulators.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 5 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on GATA-1. A trial counts if an approved drug acting on GATA-1 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.